ALLMedicine™ Hyperviscosity Syndrome Center

Feb 28th, 2023 - Multiple myeloma (MM) is the second most common hematological tumor after non-Hodgkin's lymphoma. The tumor cells originate from plasma cells in the blood pulp and are classified as plasma cells blood myeloma plasmacytomas by the WHO Tumor. It is ...

Feb 23rd, 2023 - Waldenström macroglobulinemia is a rare hematological malignancy and is the most common diagnosis in patients with hyperviscosity syndrome. Bilateral central retinal vein occlusion as an initial presentation of hyperviscosity syndrome in Waldenstr...

Feb 10th, 2023 - Walsdenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. Clinical manifestations of the hyperviscosity syndrome (HVS) are related to the large ...

Dec 22nd, 2022 - Hyperviscosity syndrome (HVS) is an infrequent but life-threatening complication of multiple myeloma (MM) and classically presents with the triad of mucosal bleed, neurological, and visual disturbances. HVS is typically associated with immunoglobu...

Sep 28th, 2022 - Waldenström macroglobulinemia is an incurable disease, despite advances in the use of targeted therapy. To assess the effectiveness of intensive induction immunochemotherapy and its combination with targeted drugs and subsequent autologous stem ce...

Feb 28th, 2023 - Multiple myeloma (MM) is the second most common hematological tumor after non-Hodgkin's lymphoma. The tumor cells originate from plasma cells in the blood pulp and are classified as plasma cells blood myeloma plasmacytomas by the WHO Tumor. It is ...

Feb 10th, 2023 - Walsdenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. Clinical manifestations of the hyperviscosity syndrome (HVS) are related to the large ...

Jul 9th, 2022 - "Hey, you know any good podcasts?" I remember asking my senior fellows this very question when I started my fellowship a few years ago. As a resident, I had enjoyed listening to a broad range of podcasts discussing current topics and fundamental ...

Oct 6th, 2021 - Stephen Ansell, MD, PhD, professor of medicine at the Mayo Clinic in Minnesota, describes the symptoms associated with Waldenström Macroglobulinemia (WM), an indolent non-Hodgkin lymphoma caused when lymphoplasmacytic cells multiply abnormally. T...

Feb 5th, 2021 - This transcript has been edited for clarity. Matthew F. Watto, MD: I am Dr Frank Watto, and that is Dr Stuart K. Brigham. With us is our good friend, Dr Paul Nelson Williams. Paul N. Williams, MD: This time around we are going to talk about our ep...

Feb 1st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

Oct 13th, 2020 - Derek C. Galligan, MD, medical oncologist, Center for Health & Healing Building, Oregon Health & Science University, discusses the utility of up-front high-intensity therapy for patients with multiple myeloma. In general, patients with newly d...